Biomarker-Based Treatment Response After Switching From Benralizumab to Tezepelumab in Refractory Allergic Bronchopulmonary Mycosis
Journal of Investigational Allergology and Clinical Immunology · 27.07.2026 · 36 (4) · 324-326
DOI: 10.18176/jiaci.1174 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigational Allergology and Clinical Immunology, online erschienen am 29.07.2026. Verfasst von Yasuhito Suzuki und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Zitieren
APA
Suzuki, Y., Saito, J., Rikimaru, M., Yamada, R., Egawa, T., Kumanaka, T., Tanaka, R., Kazama, K., Saito, K., Harigane, R., Sato, R., Tomita, H., Watanabe, N., Umeda, T., Togawa, R., Sato, Y., Wang, X., Kanazawa, K., Tanino, Y., & Shibata, Y. (2026). Biomarker-Based Treatment Response After Switching From Benralizumab to Tezepelumab in Refractory Allergic Bronchopulmonary Mycosis. Journal of Investigational Allergology and Clinical Immunology, 36(4), 324-326. https://doi.org/10.18176/jiaci.1174
Vancouver
Suzuki Y, Saito J, Rikimaru M, Yamada R, Egawa T, Kumanaka T, et al. Biomarker-Based Treatment Response After Switching From Benralizumab to Tezepelumab in Refractory Allergic Bronchopulmonary Mycosis. Journal of Investigational Allergology and Clinical Immunology. 2026;36(4):324-326. doi:10.18176/jiaci.1174
BibTeX
@article{Suzuki2026,
author = {Suzuki, Yasuhito and Saito, Junpei and Rikimaru, Mami and Yamada, Ryuki and Egawa, Tetsuya and Kumanaka, Takahiro and Tanaka, Ryutaro and Kazama, Kentaro and Saito, Koshi and Harigane, Rina and Sato, Riko and Tomita, Hikaru and Watanabe, Natsumi and Umeda, Takashi and Togawa, Ryuichi and Sato, Yuki and Wang, Xintao and Kanazawa, Kenya and Tanino, Yoshinori and Shibata, Yoko},
title = {Biomarker-Based Treatment Response After Switching From Benralizumab to Tezepelumab in Refractory Allergic Bronchopulmonary Mycosis},
journal = {Journal of Investigational Allergology and Clinical Immunology},
year = {2026},
volume = {36},
number = {4},
pages = {324--326},
doi = {10.18176/jiaci.1174}
}
EUVIMED